Home › Acute Myeloid Leukemia › NCT06472128

Novel Digital Application for Patients With Acute Leukemia

Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia

Who can join

Ages 18 to 120 · All sexes

Inclusion Criteria:

* Hospitalized patients (age \> 18 years) with a diagnosis of AML.
* Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
* Ability to comprehend and speak English as the digital apps are only available in English

Note: Patients newly diagnosed as well as those with relapsed/refractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.

Exclusion Criteria:

* Patients with a diagnosis of acute promyelocytic leukemia
* Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.

About the study

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.

What is being tested

• DREAMLAND (behavioral)
• VITAL WELLNESS (behavioral)

Sponsor: Massachusetts General Hospital · Participants: 200 · Started: Oct 21, 2024

Contact the study team

• Areej El-Jawahri, MD · Phone: 617-724-4000

Official record on ClinicalTrials.gov — NCT06472128

Locations in the U.S.

Conditions

• Acute Myeloid Leukemia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.